Company Filing History:
2 out of 1,745 
2 out of 109 
2 out of 24 Years Active: 2017-2018
Title: Herve Puy: Innovator in Erythropoietic Protoporphyria Treatments
Introduction
Herve Puy, a distinguished inventor based in Paris, France, has contributed significantly to the field of biotechnology and medicine. With a focus on addressing rare medical conditions, he is the holder of two notable patents specifically aimed at the treatment of erythropoietic protoporphyria, a genetic disorder that impacts heme production.
Latest Patents
Puy’s latest patents revolve around innovative methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria. These inventions include a unique method for increasing the amount of functional FECH in erythroid cells harboring specific genetic mutations. The techniques involve the use of antisense oligonucleotides (ASO) to prevent the splicing of a cryptic exon located in mutant FECH mRNA, thereby enhancing the therapeutic capability against this condition.
Career Highlights
Throughout his career, Herve Puy has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Paris Diderot - Paris 7. His work has consistently aimed at bridging gaps in medical research and developing practical solutions for patients affected by genetic disorders.
Collaborations
Puy has collaborated with esteemed professionals in his field, including Laurent Gouya and Jean-Charles Deybach. These partnerships have been instrumental in advancing his research and facilitating breakthroughs in treatments for erythropoietic protoporphyria.
Conclusion
Herve Puy’s innovative approach and dedication to medical research highlight the importance of continuous development in treating rare genetic disorders. His patents not only reflect significant scientific advancements but also offer hope to patients affected by erythropoietic protoporphyria, demonstrating the critical role of inventors in the medical landscape.